Sirtex Medical Deal Elevated With Liver Cancer Therapy: Real M&A
9/17/2012 7:41:40 AM
A radiation treatment that attacks cancer in the liver from the inside is putting Sirtex Medical Ltd. (SRX) back into the takeover spotlight. Even after Sydney-based Sirtex’s earnings outpaced 99 percent of specialty pharmaceuticals companies in developed Asia in the past four years, according to data compiled by Bloomberg, profit may double by 2015 as more patients get Sirtex’s therapy, UBS AG estimates. The $494 million company is tripling manufacturing capacity in the U.S., its largest market, as it forecasts a “significant increase” in demand.